How have the shares performed?
Adaptimmune Therapeutics plc (ADAP) saw an uptrend of 0.65% in the recent trading with $4.65 being its most recent. The current price level -58.48% lower than the highest price of $11.20 marked by the stock while trading over the past 52-weeks, whereas it is 22.69% higher than the lowest price of $3.79 the company dropped to over past 52-weeks. The latest news story on ADAP appeared in Simply Wall St. under the title “Adaptimmune Therapeutics (NASDAQ:ADAP) Is In A Good Position To Deliver On Growth Plans” on Jun-06-21.
Squeezing the time span to 30 day period shows us the stock is currently trading -16.67% below one month high and is +4.49% above of the lowest during that time. Looking into the simple moving average, Adaptimmune Therapeutics plc (ADAP)’s stock stands at a SMA-50 of $5.04 while that of 5-day is reading $4.66.
Daily rise and fall of price influence many of the traders, and in order to overcome the fluctuating effect of that and to watch the stock closely, traders focus more on stock’s 200-day moving average. At various points in trading activity, investors are more likely to be making use of that measure as a strong indicator in figuring out their support and resistance levels, and ADAP’s SMA-200 as of now is $5.83.
Do analysts rate it as a buy, sell or hold?
Irrespective of recent performance, what’s important is what the future holds. In uncertain economic times, a clear picture is difficult to get. Analysts generally have a good understanding of the market works, which gives them a leg up in making predictions. Currently, the stock has been recommended as Moderate Buy by 8 of the brokerage firms. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 2.60 for the stock.
Adaptimmune Therapeutics plc Earnings – What Happened With ADAP
Coming around sales and income figures, publically trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor. Adaptimmune Therapeutics plc (ADAP) last released financial results for the quarter that ended 3/30/2021, posting a surprise factor of 4.00% for net revenue. During the reported three-month period, company’s sales were $435.5 million while analysts on average were estimating the same to be $1.36 million.
ADAP – Adaptimmune Therapeutics plc Stock Earnings Estimates
The perspective of Adaptimmune Therapeutics plc (NASDAQ:ADAP)’s current quarter earnings identifies that analysts are in consensus over the estimate of -0.25 for stock’s EPS in the current quarter. 5 analysts covering the stock at Wall Street were agreed upon that EPS consensus. Company’s EPS for the last quarter was -0.24.
Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is 155.18 million. ADAP does have institutional investors; and they hold 77.30% of the stock.
Adaptimmune Therapeutics plc – Insider Activity and Holdings
Moreover, the latest SEC filings also revealed that stock came across 0 new insider purchases involving 0 shares. On the other hand, ADAP declared 0 shares have been sold in 0 insider transactions over the past three months.
As on Mar 30, 2021, Matrix Capital Management was the top most holder in Adaptimmune Therapeutics plc (NASDAQ:ADAP) with an ownership of 38.97 million shares of the company or 25.07% of the stake worth $206.95 million. The filing also reveals NEA Management Company, LLC as the second largest holder in the company with a control over 10.99% of the outstanding shares. Its stake is worth $90.71 million for having 17.08 million shares in hand.
Baillie Gifford and Company also came holding a key position in the company during the recent quarter and it now holds 7.38% of the outstanding shares. With this there are now 106 institutions which have possession in ADAP’s shares.
Currently, the stock has been recommended as Moderate Buy by 8 of the brokerage firms. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 2.60 for the stock.
The liquidity is a key characteristic of any stock and is the main point of focus of both short-term as well as long term investors before start trading into a stock. In recently reported quarter, current ratio recorded by Adaptimmune Therapeutics plc was 10.19 while posting a debt to equity ratio of 0.00. The count was 6.14 for long-term debt to equity ratio.
Adaptimmune Therapeutics plc’s return on equity, or ROE, is -39.00%, compared to the industry average of -40.20% for Healthcare – Biotechnology. Although this indicates that ADAP uses its equity well, the metric will vary significantly depending on the industry.
Technical Analysis of Adaptimmune Therapeutics plc (NASDAQ:ADAP) stock
To comprehend better with the trade moves and investors’ behavior, exploring the short, medium and long term technical indicators along with average volume of a stock is an effective way to make use of. When looking into those indicators for Adaptimmune Therapeutics plc (ADAP), we notice that the stock’s 20-day average volume is at 977,645 shares and 100% of short term indicators are suggesting the stock as Sell. Medium term indicators at an average of 100% are spotting the stock at Sell with its 50-day average volume of 844,070 shares. And to end, ADAP’s 100-day average volume is 896,008 shares with 100% of the long-term indicators pointing towards Sell for the stock.